The compound AIN457 (secukinumab) has been granted a unanimous vote of support for approval from the Dermatologic and Ophthalmic Drugs Advisory Committee to the Food and Drug Administration.
Amgen has released positive top-line results from the first of two Phase III studies of ABP 501, its candidate for the treatment of moderate-to-severe plaque psoriasis that is being developed as a biosimilar to adalimumab.
People with more severe cases of psoriasis may be at increased risk of uncontrolled hypertension, according to a study published online Oct. 15 in JAMA Dermatology.
A new drug with the potential to join the existing class of monoclonal antibodies (mAbs) for plaque psoriasis has shown promising results in a Phase II study.
Ponesimod, a selective S1P1 receptor agonist, has been shown to be efficacious for improving both disease and quality of life markers in patients with moderate to severe chronic plaque psoriasis.
Otezla (apremilast) is an oral, selective phosphodiesterase 4 (PDE4) inhibitor for the treatment of patients with moderate to severe plaque psoriasis for whom phototherapy or systemic therapy is appropriate.